Research and videos
GLP-1 (semaglutide): the research and Kevin's videos
Do GLP-1 drugs like semaglutide protect an APOE4 brain?
No Phoenix member data yet
This page has no results from Phoenix members yet. It shows what published research says, and what Kevin and the experts say in his videos.
See what Phoenix members have measuredDo GLP-1 drugs like semaglutide protect an APOE4 brain?
Semaglutide lowers weight, blood sugar and inflammation; that is well proven. In two large trials in early Alzheimer's, about six in ten of them carriers, it did not slow decline. People with diabetes who take GLP-1 drugs get dementia less often, so they may help prevent it, but no trial has tested prevention yet.
What the research says
Grade CAPOE4-specific evidence: none
GLP-1 drugs clearly improve weight and blood sugar and did not slow early Alzheimer's in two large trials; lower dementia rates in users with diabetes are a promising but unproven signal for prevention.
Key studies
Cummings 2026, Lancet (evoke and evoke+)Grade A
3,808 people with early Alzheimer's: oral semaglutide did not slow decline on CDR-SB over two years.
Read on PubMed (opens in a new tab)Tang 2025, JAMA NeurologyGrade C
Target trial emulation in about 34,000 people with type 2 diabetes: GLP-1 starters had a third lower dementia rate (observational).
Read on PubMed (opens in a new tab)Seminer 2025, JAMA NeurologyGrade C
Meta-analysis of heart and diabetes trials: GLP-1 drugs went with fewer dementia diagnoses (not a primary trial outcome).
Read on PubMed (opens in a new tab)
3 more key studies
Norgaard 2022, Alzheimer's & Dementia TRCIGrade C
Pooled diabetes trials and Danish registers: fewer dementia diagnoses on GLP-1 drugs.
Read on PubMed (opens in a new tab)Wilding 2021, NEJM (STEP 1)Grade A
Weekly semaglutide produced large weight loss in adults with obesity.
Read on PubMed (opens in a new tab)Masson 2024, Frontiers in Cardiovascular MedicineGrade A
Meta-analysis: semaglutide lowers CRP.
Read on PubMed (opens in a new tab)
What Kevin and experts say
2 passages for, 1 against, 2 with a caution, 6 also discussed
Now showing: Dr. Kevin Tran · 15:50
Open on YouTube (opens in a new tab)For2 passages
Observational data link GLP-1s with less dementia in diabetes.
“the ones taking JLP1s are getting diagnosed with dementia at a lower rate than the ones taking other diabetes drug”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
GLP-1 drugs are linked to 40% less dementia diagnosis.
“something like a GLP1 where there's an association of a 40% decreased rate of diagnosed dementia”
Dr. Grant Fraser, Board-certified anti-aging and family medicine physician, APOE4 carrier
Against1 passage
Oral semaglutide did not slow early Alzheimer's.
“the drug group got worse by 2.3 points. The placebo group got worse by 2.3 points.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
With a caution2 passages
Watch for muscle loss on GLP-1s.
“they certainly seem to have some beneficial effects for people that can tolerate a GLP-1 without becoming unhealthy as far as muscle loss or weight loss”
Dr. Grant Fraser, Board-certified anti-aging and family medicine physician, APOE4 carrier
Semaglutide may cross into the brain poorly; spinal fluid levels were about 0.4% of blood.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
Also discussed6 passages
About six in ten trial participants were APOE4 carriers.
“So let's call it six in 10 people were [APOE4] carriers.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Spinal-fluid markers fell, but people did not improve; topline data.
“The drug did actually work on the biology. It just didn't work on the people”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Real metabolic benefits; brain claims rest on mouse data.
“It's a metabolic drug in a brain drug costume.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
A failed treatment trial does not rule out prevention.
“The Alzheimer's trial failed and [GLP-1s] do nothing for your brain are actually two completely different sentences. I don't want you to glue them together.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
GLP-1 users show less dementia, but that is observational.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)Whether GLP-1 drugs prevent dementia is still untested.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
Last reviewed
The Beat the Odds Study
The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.
Turn evidence into your next test
I built this so nobody has to be the first to try something.
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Find a goal, marker, intervention or question
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.